Xeljanz woes are likely to be boost to Rinvoq, which is already growing fast – making $450 million in the first nine months of 2020, including $215 million in the third quarter alone.

The FDA has concluded its safety review of Pfizer's JAK inhibitor Xeljanz and Xeljanz XR, requiring revised warnings for the drugs as well as others in the class after finding evidence of elevated ...